Posters highlight Palatin's ocular research and PL9643 Phase
2 clinical data
CRANBURY, N.J., May 2, 2022
/PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE
American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate the
activity of the melanocortin peptide receptor system, today
announced two poster presentations at the Association for Research
in Vision and Ophthalmology (ARVO) Annual Conference being held
May 1-4 in Denver.
The posters reflect data on Palatin's novel ocular research
program and from a Phase 2 study with Palatin's compound PL9643 for
dry eye disease (DED).
Poster details:
Session: Dry Eye,
Clinical
Posterboard #: A0288
Session Date: May 2, 2022
Session Time: 2:30-4:30 pm
EDT
Poster Title: Efficacy and safety of the melanocortin
agonist PL9643 in a phase 2 study of subjects with dry eye
disease
Session: Biochemistry and Molecular Mechanisms of
Diabetic Retinopathy
Posterboard #: A0047
Session Date: May 4, 2022
Session Time: 12:00-2:00pm
EDT
Poster Title: Efficacy and impact of the melanocortin
receptor agonists PL8177 and PL9654 in an STZ-rat model of diabetic
retinopathy
The posters will be available on Palatin's website at:
www.palatin.com.
Palatin's innovative and comprehensive research regarding the
mechanism of action and efficacy of melanocortins in tissues and
animals continues to produce consistent and robust data supporting
melanocortins' role in the process of resolving inflammation and
information supporting further development of Palatin's compounds
for the treatment of inflammatory conditions.
PL9643 is a novel melanocortin agonist, delivered to the eye
topically via eyedrops. Palatin previously announced positive
results in its Phase 2 study of PL9643 for the treatment of DED.
Statistically significant improvement in multiple signs and
symptoms was achieved in the moderate to severe patient population
after 2 weeks of dosing and at the 12-week visit. There were no
safety signals identified and PL9643 had excellent ocular
tolerability.
Palatin's Phase 3 clinical study (MELODY-1) with PL9643 is
currently enrolling patients, with topline data currently expected
during the fourth quarter of calendar year 2022. If the program
progresses as planned, an NDA submission is targeted for the first
half of calendar year 2024.
About The Association for Research in Vision and
Ophthalmology (ARVO)
ARVO is the largest and most respected eye and vision research
organization in the world. Their members include nearly 11,000
researchers from over 75 countries. The mission of ARVO
is to advance research worldwide into understanding the visual
system and preventing, treating and curing its disorders.
(arvo.org)
About Dry Eye Disease (DED)
DED is a common inflammatory disease that, left untreated, can
become extremely painful and lead to permanent damage to the cornea
and vision. DED affects the cornea and conjunctiva of the eye
resulting in irritation, redness, pain, and blurred vision. It is
estimated to affect over 20 million people in the United States. The disease is
characterized by insufficient moisture and lubrication in the
anterior surface of the eye, leading to dryness, inflammation,
pain, discomfort, irritation, diminished quality of life, and in
severe cases, permanent vision impairment. Existing therapy for DED
is generally regarded as inadequate by many physicians and
patients, and often requires weeks or months to demonstrate
activity.
About Melanocortin Receptor Agonists and Inflammation
The melanocortin receptor ("MCr") system has effects on
inflammation, immune system responses, metabolism, food intake, and
sexual function. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other
places, for example, the gut and kidney) express melanocortin
receptors, empowering our opportunity to directly activate natural
pathways to resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin and natriuretic peptide receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about market potential of
Vyleesi and other Palatin products in development, clinical trial
results, potential actions by regulatory agencies including the
FDA, regulatory plans, development programs, proposed indications
for product candidates, market potential for product candidates,
and potential adverse impacts due to the global COVID-19 pandemic
such as delays in regulatory review, manufacturing and supply chain
interruptions, adverse effects on healthcare systems and disruption
of the global economy, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject to the safe
harbors created thereby. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that could
cause Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, Palatin's ability to
establish and maintain the capability for manufacturing, marketing
and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world,
results of clinical trials, regulatory actions by the FDA and other
regulatory and the need for regulatory approvals, Palatin's ability
to fund development of its technology and establish and
successfully complete clinical trials, the length of time and cost
required to complete clinical trials and submit applications for
regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-present-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2022-annual-conference-301537504.html
SOURCE Palatin Technologies, Inc.